Opyl Limited (ASX: $OPL) announces first revenue from TrialGen platform

Opyl Limited (ASX: $OPL) has announced the first revenue from its TrialGen platform, securing a contract with Brain Vector, a pioneering company in personalised mental healthcare. The total contract value is up to A$30,000 to be delivered over the term of A$5,000 per trial across up to 6 total trials. This partnership underscores Opyl's commitment to leveraging Al technology to transform clinical research and improve patient outcomes.

Executive Commentary on Opyl's Milestone Partnership

Our partnership with Brain Vector marks a significant milestone with the first revenue generated from the TrialGen platform. This collaboration underscores the immense potential and transformative impact of our Al-driven clinical trial solutions in real-world settings. By joining forces with Brain Vector, a leader in personalised mental healthcare, we are poised to drive groundbreaking advancements in mental health therapies. This partnership not only validates our innovative approach but also opens considerable future opportunities to enhance the success rates of clinical trials and improve patient outcomes globally. We look forward to leveraging our combined expertise to transform the landscape of mental health care.

Summary of Opyl's Engagement with Brain Vector

Opyl Limited (ASX: $OPL) has secured its first contract with Brain Vector, a pioneering company in personalised mental healthcare, marking a significant milestone for the company. The total contract value is up to A$30,000 and spans across 4 services, including competitor analysis, trial design optimisation, probability of success analysis simulation, and report generation. This engagement validates the value and effectiveness of Opyl's TrialGen platform in real-world clinical settings, aiming to enhance the success rates of clinical trials and support the development of groundbreaking therapies. The partnership with Brain Vector underscores Opyl's commitment to leveraging Al technology to transform clinical research and improve patient outcomes, opening up substantial opportunities for both companies to make a lasting impact on mental health treatment and improve the quality of life for countless individuals.